Latest Breaking News On - திசு ரேகேனீக்ஷ - Page 4 : comparemela.com

28 April 2021 | 09:29am StockMarketWire.com - Regenerative medical devices company Tissue Regenix posted a deeper annual loss as sales slipped and it wrote down the value of its CellRight Technologies business, acquired in 2017. Pre-tax losses for the year through December amounted to £10.2 million, compared to year-on-year losses of £7.7 million, and included a £6.1 million impairment charge on CellRight. Revenue fell 1.6% to £12.8 million, while gross profit fell 2% to £5.9 million. 2020 was a challenging year, but under the circumstances, a successful period for the group and we are pleased to have maintained consistent revenues and gross profit despite the many challenges of Covid-19, chief executive Daniel Lee said.

Daniel leeTissue regenix groupTissue regenixCellright technologiesடேனியல் லீதிசு ரேகேனீக்ஷ குழுதிசு ரேகேனீக்ஷ